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THE USE OF INTRA-ARTICULAR PLACEBO INJECTIONS TO
INVESTIGATE PAIN IN PEOPLE WITH OSTEOARTHRITIS OF THE
KNEE JOINT: A PILOT STUDY
P. Dieppe y, A. Leung z, J. Luong z, T. Pham z, K. le Marshall z, K. Lim z.
yUniv. of Exeter Med. Sch., Exeter, United Kingdom; zRheumatology Res.
Unit, Western Hosp., Melbourne, Melbourne, Australia
Purpose: Previous studies have suggested that placebo injections
into the knee joint can relieve pain in patients with knee osteo-
arthritis (KOA). It is now clear that several different types of pain
and pain mechanisms can occur in KOA: some patients have sig-
niﬁcant pain sensitisation, and a generalised pain problem compli-
cating any peripheral, nocioceptive cause. It is also known that some
20% of people who have a knee replacement do not obtain good pain
relief. We wanted to investigate the possible value of an intra-
articular injection of either a placebo or a local anaesthetic as an aid
to sorting out pain mechanisms, and helping patients and
their doctors decide whether surgery might be a good treatment
option.
Methods: The study was approved by the local ethics committee. 20
patients attending a rheumatology clinic because of bilateral, painful
KOA were recruited and gave signed, informed consent. Demographic
data was collected, including a full pain history, and the knees were
examined. Each patient then had two injections into the knee which
was causing them most pain (the index knee), with an interval of two
weeks between each injection. They were randomised to having intra-
articular Marcaine or an equivalent volume of saline ﬁrst, and the
alternative injection second, in a double blind study design. Prior to
each injection pain questionnaires were administered, including the s-
LANSS to assess neuropathic pain, and the HADs to assess the degree of
anxiety and depression. Following each injection pain scores were
collected daily in relation to both knees, for a two week period. 3
months after the end of the study all patients were recalled for follow-
up at which point they were asked about their satisfactionwith being in
the study, their preference for the ﬁrst or second injection, the overall
amount of symptom relief, whether the contralateral knee had
improved during the study, and whether being in the study had helped
them understand their pain better and decide whether surgery was for
them or not.
Results: 13 women and 7 men were recruited to the study, 14 were
Caucasian, 4 Indian and 2 Samoan, their mean age was 63 years (range
47-81). All were on some medication for their painful knee OA (18
simple analgesics, 14 NSAIDs) and they were suffering from a variety of
co-morbidities. Baseline scores indicated that 7 were complaining of
widespread pain problems in addition to knee pain, 4 had s-LANSS
scores of 12 or greater indicative of neuropathic-like pain, and 3 had a
high HADs score indicative of signiﬁcant anxiety/depression.10 patients
had Marcaine ﬁrst and 10 Saline ﬁrst. Most patients reported some pain
relief after each injection, but there were no signiﬁcant differences in
pain scores after the Marcaine or Saline: pain relief was greater after
Marcaine than Saline in 7 people, greater after Saline than Marcaine in8, and in the remaining 5 the pain relief scores were almost identical
after each injection. The total pain scores at the end of each two week
observation period showed that scores were lower at the end of the
second period than at the end of the ﬁrst, irrespective of whether
Marcaine or Saline was injected ﬁrst, and at the three month assess-
ment 13 said they favoured the second injection and 7 the ﬁrst. Four
patients reported improvement in pain in the contralateral knee. There
was no apparent difference in the response to Saline or Marcaine in
those with or without widespread pain, neuropathic pain, or anxiety/
depression. However, satisfaction with the study did differ in these
groups: fewer of those with widespread pain, neuropathic pain and
anxiety or depression reported that they got better than those without
any such features (5 of 9 compared with 9 of 11 respectively). 19 or the
20 said they were pleased to have had the chance to take part, 13 said
that it had helped greatly with their understanding of their pain
problem and 9 said it had inﬂuenced their decision about surgical
intervention.
Conclusions: There was very little difference in the pain response to
intra-articular Marcaine or Saline in this small pilot placebo study of
intra-articular injections in patients with KOA. This suggests that much
of the response to any intra-articular therapy is placebo related. The
study is too small to reach any conclusions about the value of this
approach in sorting out different pain syndromes, but we believe it
likely that it could be a helpful research tool, and out data strongly
suggest that it can be a valuable aid to doctors and patients in gaining
understanding of the pain, and in coming to appropriate treatment
decisions.
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ANALGESIC EFFICACY AND SAFETY OF CURCUMINOIDS IN CLINICAL
PRACTICE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF
RANDOMIZED CONTROLLED TRIALS
Y. Henrotin, Sr. y, A. Sahebkar, Sr. z. yBone and Cartilage Res. Unit,
Arthropo^le Liege, Univ. of Liege, Liege, Belgium; zMetabolic Res. Ctr.,
Royal Perth Hosp., Sch. of Med. and Pharmacology, Univ. of Western
Australia, Perth, Australia
Purpose: Curcuminoids are natural products with potent anti-inﬂam-
matory and antioxidant properties. There have been a number of
reports on the analgesic effects of curcuminoids in clinical trials, yet
data have not been fully conclusive. The objective of this study was to
provide the highest level of evidence on the efﬁcacy of curcuminoids in
patients with painful conditions through meta-analysis of data from
randomized controlled trials (RCTs).
Methods: A systematic review and meta-analysis was conducted using
data reported by RCTs. The primary efﬁcacy measure was pain intensity
or algofunctional status. Treatment effect was summarized with
standardized mean difference (SMD) calculated from differences in
means of pain measures between treatment and control groups using a
random-effects model.
Results: A total of 8 RCTs met our inclusion criteria, that included 606
randomized patients with diffrent painful conditions (osteoarthritis,
rheumatoid arthritis, ﬁbromyalgia). Curcuminoids were found to sig-
niﬁcantly reduce pain (SMD: -0.57, 95% CI: -1.11 to -0.03, p ¼ 0.04). This
pain-relieving effect was found to be independent of administered dose
and duration of treatment with curcuminoids, and was free from pub-
lication bias. Curcuminoids were safe and well tolerated in all evaluated
RCTs.
Conclusions: This meta-analysis of RCTs showed that supplementation
with curcuminoids is a safe and effective strategy to reduce pain severity.
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TRADITIONAL CHINESE MEDICINE FOR OSTEOARTHRITIS PAIN: A
META-ANALYSIS
B. Chen y, C. Lo z, H. Zhan y, X. Lin y, C. Wang z. y Shuguang Hosp. afﬁliated
to Shanghai Univ. of Traditional Chinese Med., Shanghai, China; z Tufts
Med. Ctr., Boston, MA, USA
Purpose: The history of oral Chinese herbal medicine is ancient, and the
therapy is considered to have analgesic effects for patients with knee
osteoarthritis (OA). We conducted a systematic review and meta-
analysis of the evidence to evaluate the efﬁcacy for pain relief of oral
Chinese herbal medicine in patients with knee OA.
Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416 A357Methods: We performed a comprehensive search on PubMed, the
Cochrane Library, the Springer Database and four Chinese Biomedical
Databases through October 2014. We included only randomized con-
trolled trials (RCTs) using oral Chinese herbal medicine as a treatment
for adults with knee OA. To determine the effect of oral Chinese herbal
medicine on clinical symptoms we extracted the Visual Analogue Scale
(VAS, range 0-10) and the Western Ontario and McMaster Universities
Arthritis Index pain scores (WOMAC pain, range 0-20), where lower
score indicates a better outcome. Study quality was assessed with Jadad
criteria regarding randomization blinding and dropout rates for each
study. VAS pain and WOMAC pain outcomes were synthesized sepa-
rately using random-effects meta-analyses.
Results: We identiﬁed 1530 potentially relevant studies. Twenty-four
studies totaling 2422 participants (64% female) met the eligibility cri-
teria. Table 1 summarizes the RCTs of oral Chinese herbal medicine on
pain measures (VAS and WOMAC scale). Subjects’ mean age was 58
years and mean symptom duration was 5.3 years. All studies were
conducted in China between 2004 and 2014; one study was published
in English. For the treatment groups, an average of 9 Chinese herbs were
prescribed for pain treatment based on the syndrome differentiation,
via infusion of the herbs with hot water and oral administration for one
to three times a day. Mean treatment duration was 6.9 weeks (range 2-
24 weeks) for 1-2 courses of treatment. No other treatments besides
herbal medicine were prescribed. Control group treatments included
oral administration of Glucosamine, non-steroidal anti-inﬂammatory
drugs (NSAIDs), Alendronate sodium, or intra-articular hyaluronate
injection. Overall quality of trials was modest (mean Jadad score¼2.9).
Nineteen studies showed signiﬁcantly improved VAS pain scores
compared to control groups (Mean Difference [MD] ¼ 0.57; 95% con-
ﬁdence interval [CI], 0.17 to 0.98; p<0.01). Six studies showed sig-
niﬁcantly improved WOMAC pain scores compared to control (MD ¼
2.23; 95% CI, 0.56 to 3.91; p<0.01).
Conclusions: These studies suggest that oral Chinese herbal medicine
has potential beneﬁts in pain relief for patients with knee OA compared
to standard westernmedications. Further rigorously designed andwell-
controlled RCTs are warranted.Table 1
Twenty-four RCTs of Chinese Herbs Medicine on Knee Osteoarthritis
Author (Year) N Age Chinese Herbs Controls
Cao, 2004 60 63 3 herbs, 0.35g3#, 3x/day Glucosamine, 0.375
Ji, 2008 50 59 9 herbs, 3x/day Glucosamine, 250m
Qi, 2009 337 55 14 Herbs: 10-30g each, 2x/day Glucosamine, 2#, 3
Li, 2012 89 61 6 herbs, 6g total, 2x/day Glucosamine, 250m
Tao, 2012 120 60 8 herbs: 10-30g each, 2x/day Glucosamine, 480m
Zhu, 2013 86 65 1 herb, 60mg total, 2x/day Glucosamine, 240m
Tang, 2014 63 55 7 herbs: 5-30g each, 2x/day Glucosamine, 750m
Ma, 2009 118 52 9 herbs: 10-15g each, 3x/day Celecoxib, 200mg,
Zhang, 2009 60 53 14 herbs: 6-30g each, 2x/day Celecoxib, 100mg,
Fan, 2012 152 50 14 herbs: 3-15g each, 2x/day Celecoxib, 200mg,
Liu, 2012 57 61 4 herbs, 1.68g total, 3x/day Celecoxib, 200mg,
Gao, 2012 96 58 9 herbs: 10-50g each, 2x/day Celecoxib, 200mg,
Diacerein, 50mg, 2
Zhang, 2013 60 55 15 herbs: 0.6-30g each, 1x/day Celecoxib, 200mg,
Fu, 2014 86 61 11 herbs: 6-15g each, 2x/day Celecoxib, 200mg,
Glucosamine, 628m
Deng, 2008 100 59 4 Herbs: 6-12g each, 1x/day Diclofenac sodium,
Kan, 2011 114 53 17 Herbs, 2.0g total, 3x/day Diclofenac sodium,
Liu, 2011 80 58 11 herbs, 1.2g total, 3x/day Diclofenac sodium,
Sun, 2012 60 57 1 herb, 1.2g total, 3x/day Diclofenac sodium,
Deng, 2009 160 60 5Herbs: 6-12 geach, 1x/day Meloxicam, 75mg,
Han, 2014 60 57 20 herbs: 5-45g each, 2x/day Meloxicam, 7.5mg,
Xie, 2010 176 60 10 Herbs, 0.5-3.0g each, 2x/day Ibuprofen, 0.6g, 2x
Lin, 2013 120 57 9 herbs: 6-30g each, 2x/day Alendronate Sodium
Lin, 2014 78 55 1 herb, 3#, 3x/day Alendronate Sodium
Yang, 2012 40 62 4 herbs: 10-20g each, 2x/day Hyaluronate injecti
N¼ number of patients included; Age reported in years as a mean; VAS Score: 0-10, lowe
Main ingredients for pain relief: White Paeony Root, Clematis Root, Doubleteeth Pubesc
Divaricate Saposhnikovia Root, Szechuan Lovage Rhizome, Manchurian Wildginger; Commo587
PREDICTING RESPONSE TO OSTEOARTHRITIS TREATMENT: PATIENT
PHENOTYPE BASED ON PATIENT REPORTED OUTCOME MEASURES
AND QUANTITATIVE SENSORY TESTING IN A CLINICAL TRIAL
K. Phillips. Univ. of Michigan, Ann Arbor, MI, USA
Purpose: Recent studies have suggested that a subset of individuals
with chronic pain state may have central sensitization. This subset of
patients with centralized pain can theoretically be identiﬁed via self
-report measures, quantitative sensory testing, and/or neuroimaging.
This study examined whether phenotyping patients by self-report or
QST measures of pain centralization predicted a differential response
amongst OA patients to a centrally-acting (duloxetine) vs. peripherally-
acting (topical diclofenac) analgesic, or both together.
Methods: Fifty patients were enrolled in a double-blind crossover trial
where each was treated with duloxetine or four times daily 1.5% topical
diclofenac solution. Outcomes included WOMAC pain subscale, Pain-
DETECT, Pain Quality Assessment Scale (PQAS), PROMIS physical func-
tion Short Form, PROMIS fatigue Short Form, Pressure Pain Threshold,
and Conditioned PainModulation. Therewere a total of three treatment
periods, each lasting for eight weeks followed by a for week washout
period. Patient were randomized as to the order in which they received
either duloxetine, topical diclofenac, or the combination. The primary
endpoint was a change in the WOMAC pain subscale.
Results: Treatment with duloxetine resulted in a signiﬁcant decrease in
WOMAC pain subscale whereas there was no signiﬁcant improvement
in the group means in the 1.5% diclofenac treatment period. QST
assessment or baseline pressure pain threshold predicted the response
to duloxetine, but there was no association between QST measures of
conditioned painmodulation and response to duloxetine. An increase in
the PainDETECT score was associated with an increase in pain as
measured by the WOMAC pain subscale by an average of 0.22 per unit
increase in pain DETECT score (SE 0.059, p¼0.0005). There were no
differences in adverse events or rescue medication usage between the
arms. There was no evidence of carry-over effect on PainDETECT scores,
p¼0.93.
Conclusions: Pain control was most favorable for duloxetine alone or in
combination with topical diclofenac. Baseline PainDETECT, PQAS Inten-
sity, and Pressure Pain Threshold predicted response to duloxetine.Duration (wks) Results (Treatment vs. Control) P value
g2#, 3x/day 4 VAS: 1.8 vs. 2.0 >0.05
WOMAC: 11 vs. 14 >0.05
g, 3x/day 6 VAS: 2.6 vs. 3.4 <0.05
x/day 4 VAS: 1.22 vs. 2.46 <0.05
g, 2x/day 8 VAS: 4.22 vs. 7.40 <0.05
g, 2x/day 8 VAS: 3.09 vs. 3.16 >0.05
g, 2x/day 12 WOMAC: 3.6 vs. 4.5 <0.05
g, 3x/day 4 WOMAC: 6.31 vs. 9.33 <0.05
1x/day 12 VAS: 2.41 vs. 3.18 <0.05
2x/day 24 WOMAC: 6.03 vs. 7.14 <0.01
1x/day 8 VAS: 2.8 vs. 2.7 >0.05
1x/day 6 VAS: 1.34 vs. 1.12 >0.05
1x/day 4 VAS: 1.94 vs. 1.56 <0.05
x/day
2x/day 4 VAS: 2.25 vs. 5.45 <0.05
1x/day 8 WOMAC: 3.19 vs. 8.51 <0.05
g, 3x/day
75mg, 1x/day 2 VAS: 1.55 vs. 1.50 >0.05
25mg, 1x/day 8 VAS: 1.93 vs. 1.93 >0.05
75mg, 2x/day 4 VAS: 3.89 vs. 4.79 <0.05
75mg, 1x/day 4 WOMAC: 13.8vs. 14.0 >0.05
1x/day 2 VAS: 2.86 vs. 3.29 >0.05
1x/day 4 VAS: 2.43 vs. 3.48 <0.01
/day 4 VAS: 2.6 vs. 4.2 <0.01
, 70mg, 1x/wk 8 VAS: 3.51 vs. 3.43 >0.05
, 70mg, 1x/wk 12 VAS: 2.42 vs. 4.17 <0.05
on, 2ml, 1x/wk 5 VAS: 3.1 vs. 3.0 >0.05
r score ¼ better outcome; WOMAC Pain Score: 0-20, lower score ¼ better outcome;
ent Angilica Root, Common Floweringquince Fruit, Slenderstyle Acanthopanax Bark,
n Monkshood Mother Root, Cassia Twig, Kusnezoff Monkshood Root.
